The AIS market comprises treatments administered to patients suffering from acute ischemic stroke (AIS), which is a medical emergency condition characterized by loss of blood circulation to an area of the brain, typically because of a clot obstructing a blood vessel. Key products operating in this market include tissue plasminogen activator (tPA), mechanical thrombectomy devices, and other drugs. Treatment with tPA within 3-4.5 hours has been shown to significantly improve patient outcomes. The use of mechanical thrombectomy devices to remove large blood clots has also demonstrated high recanalization rates. The growing geriatric population and increasing life expectancy have led to a rise in the incidence of ischemic strokes worldwide.
Key Takeaways
Key players operating in the AIS market are F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. All major companies are focusing on strengthening their product portfolios through acquisitions and partnerships. For instance, in 2021, Bristol Myers Squibb acquired Boston biotech company Synairgen for $300 million to enhance its respiratory disease pipeline. There exist ample opportunities in the Acute Ischemic Stroke Market Size owing to the increasing adoption of mechanical thrombectomy devices and emergence of novel treatment approaches. Several companies are conducting late-stage clinical trials evaluating the safety and efficacy of new drugs and devices for the treatment of ischemic strokes. Geographically, the market is anticipated to witness fastest growth in Asia owing to the rising healthcare infrastructure and healthcare expenditure in developing Asian countries.
Market Drivers
Increasing prevalence of ischemic strokes- According to World Health Organization estimates, over 17 million people suffer from strokes every year globally, of which nearly 87% are ischemic in nature. With aging populations in developed nations and risk factors like hypertension, obesity and smoking on the rise, the incidence of ischemic strokes is projected to increase substantially over the coming decade, driving the demand for effective treatment options.
Reimbursement for stroke treatment procedures - Both public and private payers in many countries provide favorable reimbursement for treatments of AIS such as thrombolytic drugs and mechanical thrombectomy. For instance, in the US, Medicare covers hospital and medical costs for stroke treatment. This encourages greater accessibility and adoption of advanced therapies.
Market Restraints
High cost of treatment - Mechanical thrombectomy devices and biologics used for ischemic strokes involve significant costs, ranging from tens of thousands to over 100 thousand dollars per patient. These expenses present affordability challenges especially in low and middle-income countries.
Limited treatment window - Only a small proportion of ischemic stroke patients presenting at healthcare facilities fall within the short therapeutic window of 3-4.5 hours for administering thrombolytic agents. Many also do not receive mechanical thrombectomy due to delays in transferring to skilled stroke centers.
Segment Analysis
Content: The acute ischemic stroke market is dominated by the t-PA drug sub segment. Tissue plasminogen activator (t-PA) also known as alteplase is currently the only drug approved by the U.S Food and Drug Administration for treating acute ischemic stroke. T-PA works by breaking down blood clots thereby restoring blood flow to the brain. It is highly effective when administered within 3-4.5 hours of onset of stroke symptoms. However, its narrow therapeutic window and risk of intracranial hemorrhage have limited its use.
Global Analysis
Content: The North America region dominates the acute ischemic stroke market and is expected to continue dominating during the forecast period. This is owing to factors such as rising healthcare expenditure, growing geriatric population who are more prone to strokes, strong presence of key market players and availability of advanced healthcare facilities. The Asia Pacific region is anticipated to be the fastest growing market between 2024-2031. This growth can be attributed to growing cases of stroke owing to changing lifestyle and increasing patient awareness about stroke treatment options in developing countries. Additionally, improving healthcare infrastructure and growing medical tourism in countries like India and China provide opportunities for market growth.
Get more insights on Acute Ischemic Stroke Market
Comments
0 comment